US biotech Immune Pharmaceuticals (Nasdaq: IMNP) saw its shares fall 6.2% to $2.59 early today, after it said it is repurchasing European and other rights to its acute myeloid leukemia (AML) treatment Ceplene (histamine dihydrochloride).
In 20012, Immune sold certain of these Ceplene-related assets to Sweden-based Meda, which in 2016 was acquired by Netherlands-incorporated Mylan (Nasdaq: MYL). Immune intends, through its immuno-oncology subsidiary Cytovia, to undertake commercialization efforts in Europe, Asia and Latin America. In addition, Cytovia intends to pursue continued development of Ceplene towards potential regulatory approval in the USA
"We are excited to regain Ceplene's European and Asian rights from Mylan and to transition Immune, through Cytovia, into a revenue-generating phase of the company's evolution. This agreement is an additional step forward towards our previously stated objective of executing a plan to establish an independent oncology business through Cytovia and follows the execution of the Letter of Intent with Pint Pharma related to licensing Ceplene in Latin America and investing in Cytovia," said Dr Daniel Teper, founder and chief executive of Immune. "Proactive maintenance treatment for acute myeloid leukemia (AML) has been recognized as highly essential for relapse prevention, and we are pleased for the potential opportunity to become a leader in the AML remission maintenance space," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze